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Prognostic Significance of Preoperative Blood 
Transfusion in Stomach Cancer
Seok Hwan Kim, Sang-Il Lee, and Seung-Moo Noh
Department of Surgery, Research Institute for Medical Science, Chungnam National Universuty School of Medicine, Daejeon, Korea
Purpose: We did a retrospective study to understand the prognostic effects of preoperative blood transfusions in stomach cancer surgery. 
Materials and Methods: Data for 1,360 patients who underwent gastrectomy for stomach cancer between 2001 and 2009 were retro-
spectively reviewed. We analyzed factors that affect preoperative transfusion and clinicopathologic features. We also analyzed 5-year and 
overall survival rates of the transfusion and non transfusion subgroups.
Results: Sixty patients (4.4%) required blood transfusion within the preoperative period. The transfused group included patients who 
took aspirin or clopidogrel (P<0.001), with more advanced T stages (P<0.001), with more advanced nodal metastasis (P=0.00), 
and with more advanced stages (P=0.00) than the non transfusion group. On multivariate analysis, preoperative transfusion was a 
statistically significant negative influence on 5-year survival and overall survival rates (58.2% vs 79.9% (P=0.00), 58.2% vs 76.8% 
(P=0.00)). Applying Cox-regression analyses, blood transfusion did appear to have an effect on prognosis and on 5-year and overall 
survival rates.
Conclusions: We found a direct negative relation between preoperative transfusion and long term prognosis in patients receiving gastric 
cancer surgery.
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Introduction
Transfusion is an important method for saving the life of pa-
tients. Nevertheless, transfusion can cause infection, and may also 
induce a hemolytic transfusion reaction, and cause an iron overload, 
post-transfusional graft versus host disease, and other side effects, 
and it may cause polycythemia.(1) Other studies have reported that 
transfusion not only causes such problems, but also, it elevates the 
recurrence rate of cancer, the rate of pertinent complications and 
the mortality rate.(2-4) 
Presently, the decision to do a transfusion is decided on by 
numerous clinicians with different educational backgrounds and 
points of view. At each medical institution, their own transfusion 
standard is taught orally and transfusion is decided accordingly. As 
a means to resolve such problems, guidelines for appropriate trans-
fusion have been suggested not only in developed countries but also 
in Korea.(5) However, a common standard value for transfusion 
can not be applied to all patients because factors associated with 
patients are very diverse.(6,7)
In the treatment of cancer patients, cases requiring transfusion 
can be broadly divided into three types: (i) cases with low presur-
gical hemoglobin values, (ii) cases where cancer surgery induces 
substantial hemorrhage, and (iii) cases in which depressed marrow 
develops due to chemotherapy or radiation therapy.(8)
Different outcomes of preoperative transfusion on the survival 
rate of gastric cancer patients have been reported.(9-12) Since 
postsurgical hemorrhage is a complication caused by erroneous sur-
gical techniques, in cases that have this complication it is a problem 
to analyze the effect of transfusion itself on the survival rate. In ad-
dition, it has been reported that regardless of transfusion, the loss of Stomach Cancer and Transfusion
197
blood itself increases the recurrence rate of cancer.(13) Therefore, 
in patients who underwent a gastrectomy for gastric cancer, we ex-
amined the effect of transfusion on survival rate by retrospectively 
analyzing the group who received preoperative transfusion and the 
group who did not receive preoperative transfusion.
Materials and Methods
Among patients diagnosed with gastric adenocarcinoma initially, 
and who underwent a gastrectomy in the department of surgery, 
Chung Nam National University Hospital, between January 2001 and 
December 2009, retrospective analysis was performed. There were 
1,542 patients whose data could be assessed. Gastrectomy was per-
formed by the same surgeon according to standardized techniques. 
To reduce errors in survival rate, cases where surgery was performed 
for radical gastrectomy but distant metastasis as well as for peritoneal 
metastasis were excluded from this study. These were evident mac-
roscopically and thus these patients underwent palliative gastrectomy 
(N=120). In addition, to reduce errors in survival rate caused by 
surgical complications, transfusions performed for hemorrhage oc-
curring during surgery and after surgery were excluded (N=62). Even 
patients who received a transfusion prior to surgery and received a 
transfusion again during surgery or after surgery were excluded from 
this study. Therefore, the patients included in this study were 1,360 
patients who received transfusion prior to surgery.
The transfusion group was defined as cases who received a trans-
fusion of concentrated red blood cells, during the transfusion period. 
This period was defined as cases who received transfusion within 
the 30 days prior to surgery. The standard for transfusion was that 
transfusion was performed for cases with hemoglobin values lower 
than 8 g/dl, where the vital signs were stable, and where there were 
no anemic symptoms, and where transfusion was decided by re-
evaluating hemoglobins. For cases with hemoglobin values of 8~10 
g/dl, transfusion was performed considering risk factors associated 
with inappropriate oxygenation (rate of blood loss, cardiopulmonary 
capacity, oxygen consumption, coronary artery diseases, etc.). For 
patients who found it difficult to adjust to anemia (those older than 
65 years, cases associated with cardiovascular or respiratory diseases), 
cases with hemoglobin lower than 10 g/dl received transfusions.
Clinicopathological factors of the transfusion group and the non-
transfusion group were analyzed. Age, gender, body mass index, and 
comorbid diseases were included in the analysis. For recurrent cases, 
a history of aspirin or Clopidogrel intake, cancer stage, the status of 
gastric outlet obstruction, and transfusion volume were included.
To determine the stage of gastric cancer, we used the AJCC 
classification (2002, 6th edition). For the evaluation of clinicopatho-
logical factors, chi-square tests were performed. For the analysis of 
the survival rate of patients, the Kaplan-Meier method was applied. 
For the validation of significance, the log-rank test was applied. 
Multivariate analysis was performed applying a Cox proportional 
regression model. We examined whether preoperative transfusion is 
an independent prognostic factor that affects survival rate.
For statistical analysis, we used SPSS for Windows (SPSS Inc., 
Chicago, IL, USA).
Results
1. Patient characteristics
The study was conducted on 1,360 patients. The characteris-
Table 2. Transfusion group according to the transfusion volume
Features
Transfusion (N=60)
N%
Transfusion volume (ml)
  <1,000 34 56.7
  1,000~2,000 22 33.7
  ≥2,000 4 9.6
Table 1. Patient characteristics (N=1,360)
Transfusion
(N=60)
Non transfusion
(N=1,300)
P-
value*
Age (year)    60 (62.5, 35~81)    61 (59.4, 26~89) 0.943
BMI (kg/m
2) 23.8 (23.7, 16.1~31.2) 23.1 (23.3, 14.9~35.7) 0.783
Transfusion 
 (ml)
800
(1,066.7, 200~4,800)
0
Admission
  Hb (g/dl)
  Hct (%)
Preoperative
  Hb (g/dl)
  Hct (%)
Postoperative
  Hb (g/dl)
  Hct (%)
POD#1
  Hb (g/dl)
  Hct (%)
  7.2 (7.1, 3.6~9.8)
23.2 (23.2, 11.0~31.2)
10.3 (10.4, 7.0~16.8)
31.3 (31.3, 10.9~48.3)
10.3 (10.6, 7.4~16.5)
31.5 (31.5, 20.7~46.2)
  9.5 (9.9, 7.7~16.0)
29.5 (30.0, 24.8~44.6)
14.0 (13.7, 7.2~18.1)
40.7 (40.4, 22.3~45.6)
14.0 (13.6, 7.2~18.1)
40.7 (40.4, 22.3~45.6)
12.9 (12.7, 8.1~17.5)
37.3 (36.8, 24.4~49.0)
12.0 (11.8, 8.2~16.7)
35.2 (35.0, 26.2~47.0)
BMI = body mass index; Hb = hemoglobin; Hct = hematocrit; POD = 
postoperative day; Data were median (mean, range). *Chi-square test.Kim SH, et al.
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tics of the patients are described in Table 1. There were 975 males 
(71.7%) and 385 females (28.3%). In the transfusion group, there 
were 43 males (71.7%) and 17 females (28.3%). In the non-trans-
fusion group, there were 931 males (71.7%) and 368 females (28.3%). 
Table 3. Patients’ clinicopathologic characteristics according to the subgroups
Features N=1,360
Transfusion (N=60) Nontransfusion (N=1,300)
P-value*
N% N%
Age groups 0.398
  <65 819 33 4.0 786 96.0
  ≥65 541 27 5.0 514 95.0
Sex 0.997
  Male 975 43 4.4 932 95.6
  Female 385 17 4.4 368 95.6
Recurrence  0.251
  Yes 28 0 0 28 100
  No 1,332 60 4.5 1,272 95.5
Gastric outlet obstruction 0.565
  Yes 69 4 5.8 65 94.2
  No 1,291 56 4.3 1,235 95.7
Comorbidity 0.644
  Yes 285 14 4.9 271 95.1
  No 1,075 46 4.3 1,029 95.7
Medication  0.000
  Yes 50 46 92.0 4 8.0
  No 1,310 14 1.1 1,296 98.9
T category 0.000
  T1 690 24 3.5 666 96.5
  T2 278 4 1.4 274 98.6
  T3 370 31 8.4 339 91.6
  T4 22 1 4.5 370 95.5
N category 0.036
  N0 795 27 3.4 768 96.6
  N1 296 15 5.1 281 94.9
  N2 176 9 5.1 167 94.9
  N3 93 9 9.7 84 90.3
Stage 0.010
  I 812 24 3.0 788 97.0
  II 166 10 6.0 156 94.0
  III 277 17 6.1 260 93.9
  IV 105 9 8.6 96 91.4
BMI (kg/m
2) 0.425
  <20 191 5 2.6 186 97.4
  20≤ ≤25 774 36 4.7 738 95.3
  ≥25.1 395 19 4.8 376 95.3
BMI = body mass index. * Chi-square test.Stomach Cancer and Transfusion
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The median age of the transfusion group and the non-transfusion 
groups was, respectively, 60 years (range: 35~81 years) and 61 
years, (range: 26~89 years).The median body mass index of the 
two groups was 23.8 kg/m
2 (16.1~31.2) and 23.1 kg/m
2 (14.9~35.7), 
respectively (Table 1).
There were 60 patients (4.4%) who received a transfusion prior 
to surgery. The median transfusion volume was 800 ml (range: 
200~4,800 ml). The median Hb values of the transfusion group 
(i) at the time of admission, (ii) prior to surgery, (iii) after surgery, 
and (iv) 1 day after surgery were 7.2 g/dl (3.5~9.8 g/dl), 10.3 g/
dl (7.0~16.8 g/dl), 10.3 g/dl (7.4~16.5 g/dl), and 9.4 g/dl (7.7~16.0 
g/dl), respectively. The analogous median Hb values of the non-
transfusion group were 14.0 g/dl (7.2~18.1 g/dl), 14.0 g/dl (7.2~18.1 
g/dl), 12.9 g/dl (8.1~17.5 g/dl), and 12.0 g/dl (8.2~16.7 g/dl), re-
spectively (Table 1).
2. Transfusion
Of the 1,360 patients who had a gastrectomy, 60 patients re-
ceived a preperative transfusion (4.4%). 34 patients (56.7%) received 
a transfusion volume less than 1,000 ml, 22 patients (33.7%) re-
ceived 1,000~2,000 ml, and 4 patients (9.6%) received more than 
2,000 ml (Table 2). We used a Chi-square test to evaluate clinico-
pathological factors of patients, especially factors associated with 
transfusion. For patients taking aspirin or Clopidogrel (P=0.00), 
cases in an advanced T stage (P=0.05), cases with more lymph node 
metastasis (P=0.00), and cases whose disease stage of gastric cancer 
was higher, more transfusions were performed (P=0.00) (Table 3).
We did a subgroup analysis for patients that had used aspirin 
or Clopidogrel (Table 4). It was found that cases who had taken 
aspirin only (P=0.00), Clopidogrel only (P=0.00), and both (P=0.00) 
received significantly more transfusions.
The number of comorbid diseases at the time of surgery 
(P=0.264) and the status of those comorbid diseases (P=0.644) did 
not receive significantly more transfusions (Table 5).
When multivariate analysis was performed on the association 
between clinicopathological factors and transfusions, no significant 
factors were detected.
3. Survival rate
The 5-year survival rate of the transfusion group was 58.2% 
for the non-transfusion group it was 79.9%, and this difference 
was significant (P=0.00) (Fig. 1A). Regarding the overall survival 
rate, similarly, the transfusion group had a rate of 58.2%, the non-
transfusion group 76.8%, and the difference was significant (P=0.00)
(Fig. 1B). The patient group that received transfusions of 0~1,000 
ml transfusion or 1,000~2,000 ml had lower 5-year survival and 
overall survival rates than the non-transfusion group; this differ-
ence was not significant (Fig. 2).
In univariate analysis, factors exerting effects on survival rate 
were transfusion prior to surgery (P=0.00), high Charlson comor-
bidity index score (P=0.001), patients with comorbidity (P=0.005), 
recurrent gastric cancer (P=0.00), large transfusion volumes (P=0.00), 
cases taking aspirin or clopidogrel (P=0.00), and disease stage 
(P=0.03). To determine whether transfusions had an independent 
effect on prognosis, we did multivariate analysis. Factors that may 
mediate adverse effects on prognosis were selected, and analysis 
was done using a Cox-regression model. Significant factors includ-
ed disease recurrence (P=0.00), cases with a high Charlson comor-
 Table 4. Medications
Features N=1,360
Transfusion (N=60) Nontransfusion (N=1,300)
P-value*
N% N %
Only aspirin 0.000
  Yes 27 24 88.9 3 11.1
  No 1,333 36 2.7 1,297 97.3
Only Clopidogrel 0.000
  Yes 7 7 100 0 0.0
  No 1,353 53 3.9 1,300 96.1
Two drugs 0.000
  Yes 16 15 93.8 1 6.3
  No 1,344 45 3.3 1,299 96.7
*Chi-square test.Kim SH, et al.
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bidity index score (P=0.002), and cases who received transfusion 
prior to surgery (P=0.00) (Table 6).
The above factors that exerted effects on survival rate were 
compared with the survival rate of patients who received a preop-
erative transfusion. Examining the 5-year survival rate of patients 
with comorbid diseases according to the status of transfusion, the 
transfusion group and the non-transfusion group were 42.9% and 
73.8%, respectively, and there was the statistically significant dif-
Table 5. Comorbidity
Features N=1,360
Transfusion (N=60) Nontransfusion (N=1300)
P-value*
N% N %
Comorbidity 0.644
  Yes 285 14 4.9 271 95.1
  No 1,075 46 4.3 1,029 95.7
Charlson comorbidity index score 0.188
  2 1,158 50 78.1 1,108 85.5
  3 140 9 14.1 131 10.1
  4 29 2 3.1 27 2.1
  5 29 2 3.1 27 2.1
  6 3 1 1.6 2 0.2
  7 1 0 0 1 0.1
Comorbidity
 Diabetes mellitus 0.467
   Yes 143 8 5.6 135 94.4
   No 1,217 52 4.3 1,165 95.7
 Hypertension 0.593
   Yes 166 6 3.6 160 96.4
   No 1,194 54 4.5 1,140 95.5
 Cerebral infarction 0.515
   Yes 42 1 1.7 41 97.6
   No 1,318 59 4.5 1,259 95.5
 Coronary disease 0.515
   Yes 42 1 2.4 41 97.6
   No 1,318 59 4.5 1,259 95.5
 Congestive heart failure 0.495
   Yes 10 0 0.0 10 100
   No 1,350 60 4.4 1,290 95.6
 Chronic renal failure 0.071
   Yes 14 2 14.3 12 85.7
   No 1,345 58 4.3 1,288 95.7
 COPD 0.953
   Yes 24 1 4.2 23 95.8
   No 1,336 59 4.4 1,277 95.6
 Liver cirrhosis 0.887
   Yes 26 1 3.8 25 96.2
   No 1,334 59 4.4 1,275 95.6
COPD = Chronic obstructive pulmonary disease. *Chi-square test.Stomach Cancer and Transfusion
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ference (P=0.02). Similarly, overall survival rates were 42.9% and 
69.4%, respectively, and a significant difference was found (P=0.004). 
Among those without comorbid diseases, the transfusion and non-
transfusion groups had 5-year survival rates of 62.9% and 73.9%, 
respectively (P=0.0023), overall survival rates were 62.9% and 
78.6%, respectively, both differences were significant.
In cases of disease recurrence, none of the patients received a 
transfusion prior to surgery. Examining the nonrecurrent group, the 
5-year survival rates of the transfusion and non-transfusion groups 
were 58.2% and 80.5%, respectively (P=0.00), overall survival rates 
were 77.6% and 68.2%, respectively (P=0.00). Both differences were 
statistically significant.
Discussion
Among studies that have analyzed factors associated with red 
blood cell transfusion in surgery, and reviewing the results of stud-
ies pertinent to surgery for cancer, Benoist reported that in rectal 
cancer surgery, in cases older than 65 years, cases with heavier 
Table 6.  Multivariate analysis
Factors P-value Exp (B) RR (95% CI)
Age 0.081 1.009 0.999~1.019
Sex 0.899 1.017 0.790~1.317
Stage 0.259 0.937 0.836~1.050
CCI 0.002 0.789 0.679~0.916
Reoperation 0.446 2.158 0.300~15.516
Recurrence 0.000 0.385 0.227~0.651
Comorbidity 0.009 0.707 0.546~0.916
Transfusion* 0.000 0.423 0.280~0.637
RR = relatvie risk; CI = confidence interval; CCI = Charlson 
comorbidity index score. *Preoperative transfusion.
Fig. 1. Preoperative blood transfusion and survival rate according to subgroup analysis. (A) 5-year survival. (B) Overall survival .
Fig. 2. Survival rate according to the volume of transfusion. (A) 5-year survival. (B) Overall survival. Kim SH, et al.
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body weight, and cases with presurgical hemoglobin values lower 
than 12.5 g/dl, red blood cell transfusion was performed more fre-
quently.(14) Vamvak as and Carven(15) reported that in colorectal 
cancer surgery, in cases with cardiovascular diseases or congestive 
heart failure, cases with diabetes, cases who were anemic prior to 
surgery, cases older than 75 years and cases that were female, red 
blood cell transfusion was performed more frequently. Matsumata 
et al.(16) reported that in liver cancer surgery, low body weight was 
a factor causing red blood cell transfusion.
In our study, which was on gastric cancer surgery, factors as-
sociated with red blood cell transfusion were analyzed. The results 
of Chi-square tests show that significant factors were cases who 
had taken aspirin or Clopidogrel (P=0.000), cases with an advanced 
T-stage category (P=0.000), those with advanced lymph node me-
tastasis (P=0.036), and cases with advanced disease stage (P=0.010) 
(Table 2). The frequency of transfusion was higher in T1 and the 
frequency of transfusion was lower in T4, which is thought to 
be due to the fact that the number of T4 patients was very small, 
only 22 patients. Multivariate analysis was performed on the above 
statistically significant factors by binary logistic regression, and no 
factors statistically significant. Our interpretation is that the factors 
were not independent factors.
Transfusion has been reported to raise the survival rate of pa-
tients with a transplanted kidney.(17) But that study was done prior 
to the development of immune suppressors, and transfusion was 
performed routinely to suppress immune reactions. In addition, 
based on the results of studies in which transfusion reduces disease 
recurrence in autoimmune diseases, transfusion could be considered 
to work through immune suppression. The effect of transfusion on 
the regulation of immunity has caused great problems in surgery 
outcomes. According to a study reported by Taylor et al.(18) which 
followed 1,717 trauma patients in the intensive care unit, it was 
shown that nosocomial infections were 6 times higher in the trans-
fusion group than in the non-transfusion group, and mortality was 
2 times higher. Other studies showed similar results that transfusion 
lowers survival rates for gastric cancer, colon cancer, rectal cancer, 
breast cancer, lung cancer, and renal cancer.(19-22) We examined 
the mechanism for the alteration of immune function after transfu-
sion. Hematopoiesis function in vivo was decreased, the functioning 
of natural killer cells and phagocytic cells was impaired, the activity 
of T-helper cells was reduced, the activity of T-suppressor cells 
were increased, and interleukin-2 production was reduced. There-
fore, patients who receive a transfusion develop serious problems in 
resistance to infection and in cancer metastasis.(23) 
In our study, similarly, the survival rate of the transfusion group 
was shown to be significantly lower than of the non-transfusion 
group. The transfusion volume did not correlate with the survival 
rate. Hence, it is thought that the transfusion itself mediated its ef-
fects on the survival rate rather than the transfusion volume. When 
the survival rate was re-examined, and we excluded recurrent cases 
and cases with comorbid diseases that have been determined to be 
factors exerting effects on survival rates by multivariate analysis, 
the survival rate was significantly lower in the transfusion group 
than in the non-transfusion group. In our study, since recurrent 
patients did not receive a transfusion, their survival rate could not 
be compared. However, as shown by multivariate analysis, it can be 
concluded that preoperative transfusion lowers the survival rate of 
gastric cancer patients (Table 6). 
Among patients with comorbid diseases, and where the pre-
surgical hemoglobin value was lower than 10.0 g/dl, 10 patients did 
not receive a transfusion. Among patients without comorbid dis-
eases and where the presurgical hemoglobin value was lower than 
8.0 g/dl, 2 patients did not receive a transfusion (Table 7). Among 
them, there were 3 cases of patients who died within 5 years. The 
causes of death were: complications caused by peritoneal metas-
tasis 5 months after surgery, deterioration of a cerebral infarction, 
and complications caused by disease recurrence that developed 1 
year after surgery. In the patient who died due to deterioration of a 
cerebral infarction, hemoglobin values prior to surgery, after sur-
gery, and one day after surgery were 9.1 g/dl, 8.3 g/dl, and 8.4 g/dl, 
respectively. Nonetheless, since the patient did not show abnormal 
vital signs or other abnormalities, transfusion was not performed. 
Three days after surgery, the patient suddenly showed cerebral in-
farction symptoms and was transferred to the department of neu-
rology. During treatment in the intensive care unit, he died on the 
day of transfer to the neurology department. The patient was taking 
aspirin for cerebral infarction and discontinued it for 7 days prior 
to surgery, but problems did not develop during surgery. Aspirin 
might affect the deterioration of a cerebral infarction. Nonetheless, 
his low hemoglobin value might have had adverse effects. After 
reviewing the case of this patient, we think that the case definitely 
required an appropriate transfusion.
In the late 1980s, as attention came to be paid to the problems 
of the spread of acquired immune deficiency syndrome, hepatitis, 
etc., studies in animals or humans increased.(24,25) Among such 
studies, was a report about patients who did not receive a transfu-
sion because of religious reasons. Even if their hemoglobin value 
was not within the normal range, if the intravascular volume was Stomach Cancer and Transfusion
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maintained, they could survive.(26) Therefore, to decide on whether 
to give a transfusion, factors other than hemoglobin values should 
be considered together.
An absolute standard of the appropriate time for preoperative 
transfusion has not been established yet. According to a recently 
published guideline, the lowest limit in healthy individuals has been 
suggested to be a hemoglobin value lower than 6 g/dl.(27)  None-
theless, according to the 1988 World Health Organization guideline 
for preoperative transfusion, a transfusion should not be decided 
on based on one factor only. They suggested 7 factors for the de-
termination of whether to do a transfusion:(28) (1) the severity of 
chronic anemia, (2) the presence or absence of comorbid diseases, 
(3) the volume of persistent hemorrhage, (4) clinical syndrome, (5) 
anaerobic metabolism (lactic acidosis), (6) perfusion index, and (7) 
the physiologic index-oxygen extraction ratio.
When patients with cardiovascular diseases, lung diseases, renal 
diseases, sepsis, or cerebral diseases were compared with patients 
without these diseases. The former could not withstand anemia as 
easily.(29) Similar to studies reporting that low hemoglobin val-
ues cause the deterioration of cardiovascular diseases and cerebral 
infarction, and raise mortality,(30) in our study, although only 1 
patient (8.3%), it was found that for cases with comorbid diseases 
difficult to withstand anemia, blood transfusion could be of help to 
improve survival rate.
In cancer patients with comorbidities, there are numerous previ-
ous studies that analyze the effect on the long-term prognosis or 
the decision of treatment strategies. Among the standardized mark-
ers or tools with which to evaluate the overall prognosis of patients, 
a representative one is the Charlson comorbidity index (CCI).(31) 
In our study, cases with comorbid diseases were scored by the CCI, 
and applying the score, the effect on survival rate was analyzed. 
The results from multivariate analysis showed that the CCI is a fac-
tor that exerts effects on the overall survival rate of gastric cancer 
patients. Nevertheless, in a study reported by Lübke et al.(32) it 
was reported that in gastric cancer patients, CCI was not a factor 
predicting a worse prognosis after surgery. Therefore, to see if CCI 
exerts effects on overall prognosis in gastric cancer patients, further 
studies may be required.
In this study, by excluding postsurgical transfusion or transfu-
sion during surgery and thus ruling out their potential effects on 
survival rate, the effect of preoperative transfusion could be ana-
lyzed. In addition, to rule out the effect of technical errors that 
may occur during surgery for gastric cancer, cases that developed 
hemorrhage during surgery or after surgery were also excluded. To 
examine the effect of transfusion during surgery or after surgery, 
additional studies are now required.
In some past studies, it was shown that transfusion was not an 
independent factor affecting survival rates of gastric cancer patients. 
Such a discrepancy was thought to be due to the fact that they 
all were retrospective studies, the size of the recruited groups was 
Table 7. Characteristics of patients who did not received preoperative transfusion in spite of indication cases
No. Age Comorbidity Medication Death Follow up (month) Stage Adm Hb Postop Hb POD#1 Hb
Cause of 
death
1 65 Yes DM, HTN No Yes 21 3 7.2 7.7 8.5 Seeding
2 79 Yes LC No No 94 3 8.6 7.9 7.5
3 39 Yes DM No No 97 3 8.9 8.3 7.9
4 60 Yes HTN No No 97 2 9.1 8.2 7.9
5 59 Yes DM, HTN, CI Aspirin Yes POD#3 1 9.1 8.3 8.4 CI
6 62 Yes HTN No Yes 80 2 9.2 9.4 8.6 Lung cancer
7 68 Yes HTN No No 21 2 9.3 10.5 10.0 Recurred
8 58 Yes DM, CI No No 107 3 9.4 9.8 8.5
9 62 Yes DM, COPD No No 81 1 9.5 9.2 8.5
10 67 Yes DM, HTN No No 85 1 9.9 9.3 8.0
11 65 No - No No 62 1 7.2 7.7 8.5
12 52 No - No No 108 3 7.2 7.7 8.5
Adm = admission; Hb = hemoglobin; Postop = postoperative; POD = postoperative day; DM = diabetes mellitus; HTN = hypertension; LC = liver 
cirrhosis; CI = cerebral infarction; COPD = chronic obstructive pulmonary disease.Kim SH, et al.
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different, the selection of subject patients was not consistent, and 
statistical methods were not identical. Therefore, prospective studies 
and continuous studies applying meta-analysis are required.
In our study of gastric cancer patients, using Chi-square tests, 
we found that factors associated with an increase in the frequency 
of preoperative red blood cell transfusions were aspirin or Clopi-
dogrel, an advanced T or N category, and advanced disease stage. 
These were not determined to be independent factors by binary 
logistic regression multivariate analysis. In Kaplan-Meier survival 
curves, the 5 year survival rate and overall survival rate of the 
transfusion group was significantly lower than the non-transfusion 
group. From Cox regression survival analysis, preoperative transfu-
sion was an independent factor mediating adverse effects on the 
survival of gastric cancer patients. Therefore, to achieve a better 
prognosis of gastric cancer patients, preoperative transfusion should 
not be performed if possible. Nevertheless, for patients who can not 
withstand anemia well, selective, appropriate transfusion may be 
required.
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